Evidence map›Paper›PMID 32461939›Full record

ArticleIranian journal of public health2020

P16INK4A Immunohistochemistry as a Gold Standard for Cervical Cancer and Precursor Lesions Screening.

Mahdieh Farzanehpour, Ahad Muhammadnejad, Setareh Akhavan, Amir Nader Emami Razavi, Somayeh Jalilvand, Vahid Salimi, Ebrahim Faghihloo, Ehsan Kakavandi, Mohammad Farahmand, Mohammad Shayestehpour and 2 more

Abstract read
In one paragraph

Article in Iranian journal of public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mahdieh FarzanehpourDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Ahad MuhammadnejadCancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Setareh AkhavanDepartment of Gynecology/Oncology, Imam Khomeini Hospital Complex, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Amir Nader Emami RazaviCancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Somayeh JalilvandDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Vahid SalimiDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Ebrahim FaghihlooDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ehsan KakavandiDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad FarahmandDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad ShayestehpourDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Farzad BabakhaniDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Talat Mokhtari AzadDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-risk (HR) Human papillomaviruses (HPVs) are known as the main factors implicated in the pathogenesis of cervical preinvasive and invasive lesions. Therefore, the presence or absence of HR-HPV can be followed for the prognosis of low-grade and high-grade squamous intraepithelial lesions. Since the overexpression of p16INK4a protein depends on the presence of transcriptionally-active HPV, and due to its availability and simple interpretation, it may be considered as a proper marker to diagnose cervical cancer.

methodsAn immunohistochemical analysis of p16INK4a was performed in 72 cervical tissue specimens at Imam Khomeini Complex Hospital (Tehran, Iran) from 2016 to 2018. The performance parameters were calculated and compared using receiving operating characteristics curve (ROC) details.

resultsp16INK4a is significantly up-regulated in the cervical cancer samples in comparison with that in normal samples. Moreover, the ROC data showed the potential ability of p16INK4a under determined conditions as a diagnostic marker for CIN 2-3 staging and invasive cervical cancer. The molecular typing disclosed the attendance of HPV DNA in 44.4% of cases (32/72) with a predominance of HPV type 16.

conclusionThe molecular biomarker p16INK4a can be a good candidate for the early diagnosis and prognosis of cervical cancer in HPV-infected patients. Considering the increase in the expression level of p16INK4a in cancer and precancer tissues, p16INK4a may be used for early detection of cervical cancer.

Indexed as

Human papillomavirusImmunohistochemistryp16INK4A

Identifiers

PMID32461939
PMCPMC7231710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.